Pichia pastoris has been developed as a valuable alternative to E. coli and CHO cells for production of novel protein formats such as multi-specific antibody mimetics. Lonza has developed a new XS™ Pichia expression and manufacturing platform designed to provide high product titers (up to 6 g/L) for these novel compounds along with a fast, robust and scalable manufacturing process suitable for commercial production.
The newly developed G1-3 fermentation process makes use of short, straightforward fermentation regimes for optimized space time yield. It is customizable based on the requirements of the full production process and the specifications of the production plants. Additional benefits include:
This webinar will include case studies highlighting the benefits of this expression and manufacturing platform.